Caitong International Asset Management’s Alterity Therapeutics ATHE Stock Holding History

Caitong International Asset Management’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Buy	+1	New	+$4	﹤0.01%	2727

Other funds holding ATHE

TLCM

Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caitong International Asset Management's ATHE Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Alterity Therapeutics (ATHE) in Q2 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #2727 among its holdings.

22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

Caitong International Asset Management held 1 share of Alterity Therapeutics worth $5 as of Q2 2026.
Alterity Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Alterity Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2727 holding.
22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.